AR109859A1 - BROMODOMINUM INHIBITOR - Google Patents

BROMODOMINUM INHIBITOR

Info

Publication number
AR109859A1
AR109859A1 ARP170102935A ARP170102935A AR109859A1 AR 109859 A1 AR109859 A1 AR 109859A1 AR P170102935 A ARP170102935 A AR P170102935A AR P170102935 A ARP170102935 A AR P170102935A AR 109859 A1 AR109859 A1 AR 109859A1
Authority
AR
Argentina
Prior art keywords
methylsulfonylphenyl
cyclopropylmethoxy
methylisoquinolin
pharmaceutical composition
inhibitor
Prior art date
Application number
ARP170102935A
Other languages
Spanish (es)
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of AR109859A1 publication Critical patent/AR109859A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe en la presente composiciones farmacéuticas del inhibidor del bromodominio 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona, que incluye sus formas cristalinas, formas amorfas, solvatos e hidratos. En algunas formas de realización, la composición farmacéutica comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona que se procesó por micronización o dispersión secada por pulverización. En algunas formas de realización, la composición farmacéutica también comprende al menos un polímero. En algunas formas de realización, la composición farmacéutica comprende una matriz polimérica sólida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilsoquinolin-1-ona son de utilidad para el tratamiento de cáncer o enfermedad neoplásica.Pharmaceutical compositions of the bromodomain inhibitor 4- [2- (cyclopropylmethoxy) -5-methylsulfonylphenyl] -2-methylisoquinolin-1-one, which includes its crystalline forms, amorphous forms, solvates and hydrates, are described herein. In some embodiments, the pharmaceutical composition comprises 4- [2- (cyclopropylmethoxy) -5-methylsulfonylphenyl] -2-methylisoquinolin-1-one which was processed by micronization or spray-dried dispersion. In some embodiments, the pharmaceutical composition also comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4- [2- (cyclopropylmethoxy) -5-methylsulfonylphenyl] -2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4- [2- (cyclopropylmethoxy) -5-methylsulfonylphenyl] -2-methylsoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.

ARP170102935A 2016-10-20 2017-10-20 BROMODOMINUM INHIBITOR AR109859A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20

Publications (1)

Publication Number Publication Date
AR109859A1 true AR109859A1 (en) 2019-01-30

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102935A AR109859A1 (en) 2016-10-20 2017-10-20 BROMODOMINUM INHIBITOR

Country Status (7)

Country Link
EP (1) EP3528810A4 (en)
JP (3) JP7129973B2 (en)
CN (1) CN110099685A (en)
AR (1) AR109859A1 (en)
AU (1) AU2017345468B2 (en)
TW (1) TW201821062A (en)
WO (1) WO2018075796A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642860A (en) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 Bromodomain inhibitor
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
CN112823152A (en) * 2018-07-23 2021-05-18 赛尔基因昆蒂赛尔研究公司 Methods for preparing bromodomain inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3030242A1 (en) * 2013-08-06 2016-06-15 Oncoethix GmbH Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
CN105873577B (en) * 2013-08-30 2019-06-18 西奈山伊坎医学院 Ring vinylogous amide is as bromine structural domain inhibitor
DK3640241T3 (en) * 2013-10-18 2022-11-28 Celgene Quanticel Res Inc BROMO DOMAIN INHIBITORS
EP3074018A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
TW201642860A (en) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 Bromodomain inhibitor
CN105732624B (en) * 2016-01-28 2019-08-02 中国药科大学 The preparation method and its usage of pyrroles [4,3,2-de] quinoline -2 (1H) -one class BRD4 protein inhibitor

Also Published As

Publication number Publication date
WO2018075796A1 (en) 2018-04-26
CN110099685A (en) 2019-08-06
EP3528810A4 (en) 2020-06-17
TW201821062A (en) 2018-06-16
EP3528810A1 (en) 2019-08-28
AU2017345468B2 (en) 2022-06-02
JP7129973B2 (en) 2022-09-02
JP2024056905A (en) 2024-04-23
AU2017345468A1 (en) 2019-06-06
JP2022095897A (en) 2022-06-28
JP2019535671A (en) 2019-12-12

Similar Documents

Publication Publication Date Title
ECSP17071545A (en) BROMODOMINIUM INHIBITORS
CL2019001714A1 (en) Amino-triazolopyridine compounds and their use in the treatment of cancer.
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
UY37098A (en) ROR-GAMMA MODULATORS
CL2016002169A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders.
CO2017003838A2 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CU20200042A7 (en) LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTIRRETIN
CO2019011546A2 (en) Compounds and methods for the treatment of parasitic diseases
CL2019001337A1 (en) Pharmaceutical formulations.
CL2020002624A1 (en) Stable anti-cd79b immunoconjugate formulations.
CL2017002214A1 (en) Combination formulation of tesofensin and beta blocker
AR109859A1 (en) BROMODOMINUM INHIBITOR
CO2017007076A2 (en) Indenyl compounds, pharmaceutical compositions and medical uses thereof
BR112018070497A2 (en) pharmaceutical methods and formulations for treating eye conditions
CL2018001590A1 (en) Pharmaceutical compositions comprising some phenylaminopyrimidine derivative.
CO2021007006A2 (en) Modulators of irf5 expression
CL2017000178A1 (en) Compounds for use in anthelmintic treatment
CL2018000391A1 (en) Pharmaceutical combinations and their use
CL2018001157A1 (en) Formulation of fixed dose combination, eflornithine and sulindac.
ECSP18000689A (en) SOLID PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HCV
CL2017002229A1 (en) Bace1 inhibitors.
CU20190002A7 (en) COMBINATION OF A BCL-2 INHIBITOR AND A MCL1 INHIBITOR FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
CO2020003134A2 (en) Modulators of enac expression
BR112016026684A2 (en) SULFUR-BASED FERTILIZER
CL2018003013A1 (en) Use of an acetylcholinesterase and idalopirdine inhibitor to reduce falls in patients with parkinson's disease.

Legal Events

Date Code Title Description
FB Suspension of granting procedure